BMCMI
AMRI

Bryn Mawr Capital Management Inc’s Albany Molecular Research Inc AMRI Stock Holding History

Bryn Mawr Capital Management Inc’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-25,848
Closed -$450K – 389
2015
Q3 		$450K Buy
+25,848
New +$526K 0.08% 283
2014
Q1 		– Sell
-60,147
Closed -$606K – 722
2013
Q4 		$606K Buy
+60,147
New +$727K 0.04% 279

Other funds holding AMRI

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.44B AUM 24.34% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bryn Mawr Capital Management Inc's AMRI Position: Q4 2015 in Review

Bryn Mawr Capital Management Inc sold out of Albany Molecular Research Inc (AMRI) in Q4 2015, closing a stake of 25,848 shares — an estimated $450K sold.

Bryn Mawr Capital Management Inc first reported a position in AMRI in Q4 2013 and held it in 2 quarters. The position peaked at $606K in Q4 2013. 151 funds tracked by Wall St. Rank hold AMRI as of Q4 2015.

  • Bryn Mawr Capital Management Inc reported no remaining Albany Molecular Research Inc position as of Q4 2015 after selling out during the quarter.
  • Bryn Mawr Capital Management Inc sold 25,848 Albany Molecular Research Inc shares in Q4 2015, an estimated $450K.
  • Bryn Mawr Capital Management Inc first reported a position in Albany Molecular Research Inc in Q4 2013 and held it in 2 quarters.
  • Bryn Mawr Capital Management Inc's Albany Molecular Research Inc position peaked at $606K in Q4 2013.
  • 151 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2015.

Based on Bryn Mawr Capital Management Inc's 13F filing for Q4 2015.